<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="149450">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01154751</url>
  </required_header>
  <id_info>
    <org_study_id>IDEV Technologies, Inc.</org_study_id>
    <nct_id>NCT01154751</nct_id>
  </id_info>
  <brief_title>Data Registry Following Patients Using Supera Stent in the Femoral Arteries</brief_title>
  <acronym>STRONG</acronym>
  <official_title>Supera Treatment Registry Observing Neointimal Growth</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Vascular</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott Vascular</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Long-term, observational, prospective, multicenter registry following patients who have been
      implanted with the SUPERA Interwoven Self-Expanding Nitinol Stent for treating stenosis in
      the superficial femoral and/or femoropopliteal arteries.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This registry follows up to 200 patients for at least 5 years.

      The STRONG Data Registry will follow patients under real world conditions, evaluating
      restenosis rates, periprocedural/postprocedural complications, patency, target lesion
      revascularization, walking distance, stent fractures, and adverse events/serious adverse
      events.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>November 2008</start_date>
  <completion_date type="Anticipated">August 2015</completion_date>
  <primary_completion_date type="Anticipated">August 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Target Lesion Revascularization</measure>
    <time_frame>6 months and 1 year</time_frame>
    <description>Target Lesion Revascularizatio (TLR)rates measured at 6 months and 1 year</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Peripheral Artery Disease</condition>
  <condition>Femoropopliteal Artery Stenosis</condition>
  <condition>Peripheral Vascular Disease</condition>
  <arm_group>
    <arm_group_label>Device SUPERA Stent</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>SUPERA Interwoven Self-Expanding Nitinol Stent System</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SUPERA Interwoven self-expanding nitinol stent</intervention_name>
    <description>Insertion of stent at stenotic area</description>
    <arm_group_label>Device SUPERA Stent</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Exclusion Criteria:

        (Clinical)

          -  Patient or legal guardian understands registry procedures and has voluntarily signed
             an informed consent in accordance with institutional and local regulatory policies.
             (Note: Retrospective data may be collected and entered into the EDC system after a
             fully executed informed consent has been provided).

          -  Rutherford-Becker classification 2 through 5 only

          -  Patient is at least 18 years of age and of legal age of consent.

          -  Patient must be willing to participate in the registry for at least 5 years.

        (Angiographic)

          -  Target lesion is a single de novo or restenotic (outside a stent) SFA or Popliteal
             artery lesion ≥ 1 cm from origin of another stent; additional lesions may be
             present., but there is only one target lesion

          -  All SFA target lesions are to be located with the proximal point at least 2 cm below
             the origin of the profunda femoris artery.

          -  All Popliteal Artery target lesions are to be located with the most distal point at
             least 1 cm proximal to the bifurcation of the anterior tibial artery and the
             tibioperoneal trunk.

          -  Target lesion length 1-20 cm (visual estimate)

          -  Target lesion stenosis ≥50% (visual estimate)

          -  Popliteal artery patent if the lesion is in the SFA

          -  SFA patent if the lesion is in the popliteal artery

          -  At least one widely patent (&lt; 50% stenosis) infrapopliteal artery (for distal
             run-off)

        Exclusion Criteria:

        (Clinical)

          -  Evidence of heparin induced thrombocytopenia (HIT), or intravenous tPA, Plavix,
             Ticlid, or aspirin therapy sensitivities

          -  Patient is participating in a clinical study that could confound results

          -  Patient is pregnant/breastfeeding at time enrollment or plans to become pregnant
             during the course of participation in the registry.

        (Angiographic)

          -  Target lesion length &gt; 20 cm

          -  Instent restenotic / reoccluded target lesion

          -  Acute (≤ 4 weeks) thrombotic occlusion

          -  Untreated ipsilateral pelvic stenosis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Zeller, Prof Dr med</last_name>
    <role>Principal Investigator</role>
    <affiliation>Herzzentrum Abteilung fur Angiologie, Bad Krozingen, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Herzzentrum Abteilung fur Angiologie</name>
      <address>
        <city>Bad Krozingen</city>
        <zip>79189</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heart Center Leipzig/Park Hospital</name>
      <address>
        <city>Leipzig</city>
        <zip>04289</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kathlisches Klinikum Mainz</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zentrum fur Diabetes-und GefaBerkrankungen</name>
      <address>
        <city>Munster</city>
        <zip>48145</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <lastchanged_date>August 16, 2012</lastchanged_date>
  <firstreceived_date>June 29, 2010</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Femoral artery stenosis</keyword>
  <keyword>Peripheral vascular Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Vascular Diseases</mesh_term>
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
